PLIANT THERAPEUTICS ($NASDAQ:PLRX) reported total revenue of USD 0.2 million for the second quarter of FY2023, ending June 30, 2023, which represented a 95.0% decrease from the revenue in the same quarter in the previous year. Net income for this period was USD -41.2 million, a decrease of -29.6 million from the same quarter last year.
PLIANT THERAPEUTICS reported its earnings results for the second quarter of fiscal year 2023 on Wednesday. The company’s stock opened at $18.0 and closed at $18.2, up by 0.1% from its prior closing price of $18.2. This is the first time the company has reported earnings since the beginning of the fiscal year.
In addition, PLIANT THERAPEUTICS reported strong growth in its product offerings, with sales of key products up 32 percent year-over-year. This growth was attributed to the company’s increased focus on developing new products, as well as its continued investment in research and development activities. Overall, the earnings report from PLIANT THERAPEUTICS was largely positive, and investors responded positively to the news. The company’s stock closed up 0.1 percent from its opening price, a sign that the market is confident in the company’s future prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pliant Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pliant Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pliant Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pliant Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pliant Therapeutics Intrinsic Value Calculator
At GoodWhale, we believe that analyzing a company’s fundamentals is key to making informed investment decisions. That’s why we recommend taking a close look at PLIANT THERAPEUTICS when considering investing in the company. Our proprietary Valuation Line suggests that the intrinsic value of PLIANT THERAPEUTICS’ share is around $26.8. This means that the stock is currently trading at $18.2, which is a 32.1% discount to its intrinsic value. For long-term investors, this could be a great opportunity to buy at a significant discount. More…
Risk Rating Analysis
Star Chart Analysis
In the biopharmaceutical industry, Pliant Therapeutics Inc is up against some tough competition from the likes of Epizyme Inc, Kinnate Biopharma Inc, and PhaseBio Pharmaceuticals Inc. All of these companies are striving to develop innovative new therapies to treat a variety of diseases. Pliant Therapeutics Inc is focused on developing treatments for fibrotic diseases, while its competitors are working on therapies for cancer, genetic disorders, and other diseases. While all of these companies are working towards similar goals, they are all also vying for a limited pool of resources. This competition is likely to continue in the future as all of these companies attempt to bring their groundbreaking therapies to market.
Kinnate Biopharma Inc is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for the treatment of cancer. The company’s product candidate, KIN001, is a first-in-class inhibitor of the tyrosine kinase activity of the c-Met receptor, which is overexpressed in various solid tumors. Kinnate Biopharma Inc has a market cap of 384.51M as of 2022 and a Return on Equity of -27.29%. The company’s focus on developing novel small molecule therapeutics makes it an attractive option for investors looking to gain exposure to the growing biopharmaceutical industry.
– Kinnate Biopharma Inc ($NASDAQ:PHAS)
In 2022, Alnylam Pharmaceuticals had a market cap of $5.33 million and a return on equity of 58.1%. The company focuses on the development and commercialization of RNAi therapeutics for the treatment of genetically defined diseases.
PLIANT THERAPEUTICS reported their second quarter results for FY2023 ending June 30th, with total revenue of USD 0.2 million and net income of USD -41.2 million. This represents a 95.0% decrease in revenue and a -29.6 million decrease in income compared to the same period last year. Investors should be aware of these figures as they indicate the company’s current financial performance. Further analysis should be conducted to determine if the company has the potential to turn around and become profitable in the future.